Astron Pulsar

Image
Picture of Astron Pulsar
Image
Picture of Astron Pulsar
Image
Picture of Astron Pulsar
Image
Picture of Astron Pulsar

Astron Pulsar

SELF-EXPANDING STENT
INDICATED FOR FEMORAL AND INFRAPOPLITEAL ARTERIES

Being a relatively mobile artery, the Superficial Femoral Artery (SFA) requires a stent that conforms to the natural vessel movement and provides sufficient support in complex, long lesions that are often difficult to cross. Astron Pulsar is a stent designed for SFA with high multi-directional flexibility on a low-profile delivery system.


KEY FACTS
  • S-articulating connecting bars and peak-to-valley design for multi-directional flexibility
  • Segmented stent design with thin struts for lower chronic outward force
  • Pull-back delivery system for simple stent deployment
  • Low profile 4F delivery system with 3.6 F proximal shaft for contrast injection with device in sheath


Product Details

Clinically Proven in Mid-Term Follow-Up (24 months)

Pulsar stents in shorter lesions:
4EVER1 trial. ALL 4.3 cm; PP 76.2%; FTLR 82.3%
REAP2 trial. ALL 5.2 cm; PP 68.0%; FTLR 86.2%

Pulsar stents in combination with Drug-Coated Balloon (DCB):
DEBAS3 trial. ALL 18.8 cm; PP 88.2%; FTLR 91.0%4


Astron Pulsar image

Stent Designed for SFA

  • Peak-to-valley design and S-articulating connecting bars provide multi-directional flexibility and avoid fish-scaling in mobile vessel architecture.
  • A segmented stent design with thin struts provides low chronic outward force (COF)5 sufficient to maintain vessel scaffolding even in calcified lesions (4EVER trial1). High COF has been shown to result in higher rates of neointimal hyperplasia.6, 7, 8
  • Ideal for shorter lesions, spot-stenting or combination therapy with DCB

Pull-Back Delivery System

  • Enables simple stent deployment.

Safety Tab

  • Avoids accidental stent deployment.

Easy Release

  • Relieves friction of introducer valve on the rectractable shaft during stent deployment for a smoother action.

Low Profile Delivery System

  • 4F distal shaft profile for easier lesion crossing.
  • 3.6F proximal shaft for contrast injection with device positioned inside introducer and across lesion.

4-EVER

  • Physician-initiated trial investigating the safety of the full 4F endovascular treatment approach of infra-inguinal arterial stenotic disease.
  • Number of patients (n): 120
  • Primary endpoint: Primary Patency (PP) at 12 months

Technical Data

Astron Pulsar Stent
Catheter type
OTW
Recommended guide wire
0.018"
Stent material
Nitinol
Strut thickness
155 μm
Stent coating
proBIO (amorphous silicone carbide)
Stent markers
6 gold markers on each end
Sizes
ø 4 - 7 mm; L: 20 - 80 mm
Proximal shaft
3.6 F, hydrophobic coating
Usable length
70 cm (ø 5.0 - 7.0 mm)
72 cm (ø 4.0 mm, L: 60 - 80 mm)
75 cm (ø 4.0 mm, L: 20 - 40 mm)
120 cm (ø 5.0 - 7.0 mm)
130 cm (ø 4.0 mm, L: 60 - 80 mm)
135 cm (ø 4.0 mm, L: 20 - 40 mm)

Ordering Information


Contact

contact
Country/Region
6 + 10 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

1 4EVER trial. Bosiers. M. 24m results presented at CIRSE 2013; Deloose K. 24m results presented at LINC 2014.

2 Acín. F. et al. Astron Pulsar Nitinol stent in the femoropopliteal sector. Técnicas Endovasculares 2010; 13: 3203-3211.

3 DEBAS trial. Mwipatayi P. 24-month results presented VEITH 2015.

4 DEBAS uses Pulsar-18 stent, another member of the Pulsar family with similar stent characteristics.

5 BIOTRONIK data on file.

6 Ballyk PD. Intramural stress increases exponentially with stent diameter: a stress threshold for neointimal hyperplasia. J Vasc Interv Radiol. 2006 Jul; 17(7): 1139-45.

7 Freeman JW, Snowhill PB, Nosher JL. A link between stent radial forces and vascular wall remodeling: the discovery of an optimal stent radial force for minimal vessel restenosis. Connect Tissue Res. 2010 Aug; 51(4): 314-26.

8 Zhao HQ, Nikanorov A, Virmani R, Jones R, Pacheco E, Schwartz LB. Late stent expansion and neointimal proliferation of oversized Nitinol stents in peripheral arteries. Cardiovasc Intervent Radiol. 2009 Jul; 32(4): 720-6.